Current developments in gastric cancer: from molecular profiling to treatment strategy
M Alsina, V Arrazubi, M Diez, J Tabernero - … Reviews Gastroenterology & …, 2023 - nature.com
Gastric cancer and gastro-oesophageal junction cancer represent a global health-care
challenge. Despite the efficacy of improved chemotherapy and surgical options, these …
challenge. Despite the efficacy of improved chemotherapy and surgical options, these …
Oesophageal cancer
Oesophageal cancer is the sixth most common cause of cancer-related death worldwide
and is therefore a major global health challenge. The two major subtypes of oesophageal …
and is therefore a major global health challenge. The two major subtypes of oesophageal …
[HTML][HTML] Comparative molecular analysis of gastrointestinal adenocarcinomas
We analyzed 921 adenocarcinomas of the esophagus, stomach, colon, and rectum to
examine shared and distinguishing molecular characteristics of gastrointestinal tract …
examine shared and distinguishing molecular characteristics of gastrointestinal tract …
[HTML][HTML] Integrated genomic characterization of oesophageal carcinoma
Cancer Genome Atlas Research Network - Nature, 2017 - ncbi.nlm.nih.gov
Oesophageal cancers are prominent worldwide; however, there are few targeted therapies
and survival rates for these cancers remain dismal. Here we performed a comprehensive …
and survival rates for these cancers remain dismal. Here we performed a comprehensive …
[HTML][HTML] Genetics and molecular pathogenesis of gastric adenocarcinoma
Gastric cancer (GC) is globally the fifth most common cancer and third leading cause of
cancer death. A complex disease arising from the interaction of environmental and host …
cancer death. A complex disease arising from the interaction of environmental and host …
Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity
The incidence of esophageal adenocarcinoma (EAC) has risen 600% over the last 30 years.
With a 5-year survival rate of∼ 15%, the identification of new therapeutic targets for EAC is …
With a 5-year survival rate of∼ 15%, the identification of new therapeutic targets for EAC is …
[HTML][HTML] Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy
Gastroesophageal adenocarcinoma (GEA) and squamous esophageal cancer (ESCC) are
responsible for> 1 million deaths annually globally. Until now, patients with metastatic GEA …
responsible for> 1 million deaths annually globally. Until now, patients with metastatic GEA …
Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a …
Background EGFR overexpression occurs in 27–55% of oesophagogastric
adenocarcinomas, and correlates with poor prognosis. We aimed to assess addition of the …
adenocarcinomas, and correlates with poor prognosis. We aimed to assess addition of the …
Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition
The role of KRAS, when activated through canonical mutations, has been well established in
cancer. Here we explore a secondary means of KRAS activation in cancer: focal high-level …
cancer. Here we explore a secondary means of KRAS activation in cancer: focal high-level …
Paired exome analysis of Barrett's esophagus and adenocarcinoma
Barrett's esophagus is thought to progress to esophageal adenocarcinoma (EAC) through a
stepwise progression with loss of CDKN2A followed by TP53 inactivation and aneuploidy …
stepwise progression with loss of CDKN2A followed by TP53 inactivation and aneuploidy …